ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Commentary|Videos|September 16, 2024
Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups
Author(s)Thierry Andre, MD
Fact checked by: Ashling Wahner , Kristi Rosa
Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.
Advertisement
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital, discusses findings from subgroup and safety analyses of the phase 3 CheckMate 8HW trial (NCT04008030), which investigated nivolumab (Opdivo) plus ipilimumab (Yervoy) vs chemotherapy in the frontline setting in patients with microsatellite instability–high (MSI-H), mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC).
Advertisement
Related to this article
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across 3 cohorts in resectable locally advanced HNSCC.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
The OncFive: Top Oncology Articles for the Week of 8/16
3
Bomedemstat Yields Spleen Reduction, Symptom Improvement in Advanced Myelofibrosis
4
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
5